Analystreport

Akero Therapeutics (NASDAQ: AKRO) is now covered by analysts at Canaccord Genuity. They set a "buy" rating on the stock.

Akero Therapeutics, Inc.  (AKRO) 
Last akero therapeutics, inc. earnings: 3/16 07:30 am Check Earnings Report